Rein Therapeutics, Inc. Proceeds from Collaborators
Rein Therapeutics, Inc. (RNTX) reported Proceeds from Collaborators of $34.91 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromCollaborators · last filed 2026-03-26
- Rein Therapeutics, Inc. proceeds from collaborators for the quarter ending 2025-12-31 was $0.00.
- Rein Therapeutics, Inc. proceeds from collaborators for the quarter ending 2025-09-30 was $0.00.
- Rein Therapeutics, Inc. proceeds from collaborators for the quarter ending 2025-06-30 was $0.00.
- Rein Therapeutics, Inc. proceeds from collaborators for the quarter ending 2025-03-31 was $34.91M, a 0.00% change year-over-year.
- Rein Therapeutics, Inc. proceeds from collaborators for fiscal 2025 was $34.91M, a 0.00% change from fiscal 2024.
- Rein Therapeutics, Inc. proceeds from collaborators for fiscal 2024 was $34.91M, a 0.00% change from fiscal 2023.
- Rein Therapeutics, Inc. proceeds from collaborators for fiscal 2023 was $34.91M, a 0.00% change from fiscal 2022.
- Rein Therapeutics, Inc. proceeds from collaborators for fiscal 2022 was $34.91M, a 0.00% change from fiscal 2021.
| Period end | Proceeds from Collaborators | Proceeds from Collaborators 3 month | Proceeds from Collaborators 6 month | Proceeds from Collaborators 9 month | Proceeds from Collaborators 12 month | Proceeds from Collaborators 51 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | $0.00 derived: sum of 3 quarters · filed 2026-03-26 | $34.91M 10-K · filed 2026-03-26 | ||
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $0.00 derived: sum of 2 quarters · filed 2025-11-14 | $34.91M 10-Q · filed 2025-11-14 | $34.91M derived: sum of 4 quarters · filed 2025-11-14 | ||
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $34.91M 10-Q · filed 2025-08-14 | $34.91M derived: sum of 3 quarters · filed 2025-08-14 | $34.91M derived: sum of 4 quarters · filed 2025-08-14 | ||
| 2025-03-31 | $34.91M 10-Q · filed 2025-05-15 | $34.91M derived: sum of 2 quarters · filed 2025-05-15 | $34.91M derived: sum of 3 quarters · filed 2025-05-15 | $34.91M derived: sum of 4 quarters · filed 2025-05-15 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | $0.00 derived: sum of 2 quarters · filed 2025-04-07 | $0.00 derived: sum of 3 quarters · filed 2025-04-07 | $34.91M 10-K · filed 2025-04-07 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $34.91M 10-Q · filed 2024-11-14 | $34.91M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $34.91M 10-Q · filed 2024-08-14 | $34.91M derived: sum of 3 quarters · filed 2024-08-14 | $34.91M derived: sum of 4 quarters · filed 2024-08-14 | ||
| 2024-03-31 | $34.91M 10-Q · filed 2024-05-15 | $34.91M derived: sum of 2 quarters · filed 2024-05-15 | $34.91M derived: sum of 3 quarters · filed 2024-05-15 | $34.91M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-15 | $0.00 derived: sum of 2 quarters · filed 2024-04-15 | $0.00 derived: sum of 3 quarters · filed 2024-04-15 | $34.91M 10-K · filed 2024-04-15 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-13 | $0.00 derived: sum of 2 quarters · filed 2023-10-13 | $34.91M 10-Q · filed 2023-10-13 | $34.91M derived: sum of 4 quarters · filed 2023-10-13 | ||
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $34.91M 10-Q · filed 2023-08-11 | $34.91M derived: sum of 3 quarters · filed 2023-08-11 | $34.91M derived: sum of 4 quarters · filed 2023-08-11 | ||
| 2023-03-31 | $34.91M 10-Q · filed 2023-05-08 | $34.91M derived: sum of 2 quarters · filed 2023-05-08 | $34.91M derived: sum of 3 quarters · filed 2023-05-08 | $34.91M derived: sum of 4 quarters · filed 2023-05-08 | ||
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $0.00 derived: sum of 2 quarters · filed 2023-03-20 | $0.00 derived: sum of 3 quarters · filed 2023-03-20 | $34.91M 10-K · filed 2023-03-20 | ||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $0.00 derived: sum of 2 quarters · filed 2022-11-01 | $34.91M 10-Q · filed 2022-11-01 | |||
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $34.91M 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | $34.91M 10-Q · filed 2022-05-05 | |||||
| 2021-12-31 | $34.91M 10-K · filed 2022-03-28 | |||||
| 2021-09-30 | $34.91M 10-Q · filed 2021-11-12 | |||||
| 2020-12-31 | $34.91M 10-K · filed 2021-03-24 | |||||
| 2020-03-31 | $34.91M 10-Q · filed 2020-05-11 | $34.91M derived: sum of 2 quarters · filed 2020-05-11 | $34.91M derived: sum of 3 quarters · filed 2020-05-11 | $34.91M derived: sum of 4 quarters · filed 2020-05-11 | ||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-30 | $0.00 derived: sum of 2 quarters · filed 2020-03-30 | $0.00 derived: sum of 3 quarters · filed 2020-03-30 | $34.91M 10-K · filed 2020-03-30 | ||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | $34.91M 10-Q · filed 2019-11-07 | $34.91M derived: sum of 4 quarters · filed 2019-11-07 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | $34.91M 10-Q · filed 2019-08-06 | $34.91M derived: sum of 3 quarters · filed 2019-08-06 | $34.91M derived: sum of 4 quarters · filed 2019-08-06 | ||
| 2019-03-31 | $34.91M 10-Q · filed 2019-05-08 | $34.91M derived: sum of 2 quarters · filed 2019-05-08 | $34.91M derived: sum of 3 quarters · filed 2019-05-08 | $34.91M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-29 | $0.00 derived: sum of 2 quarters · filed 2019-03-29 | $0.00 derived: sum of 3 quarters · filed 2019-03-29 | $34.91M 10-K · filed 2019-03-29 | ||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $0.00 derived: sum of 2 quarters · filed 2018-11-07 | $34.91M 10-Q · filed 2018-11-07 | $34.92M derived: sum of 4 quarters · filed 2018-11-07 | ||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $34.91M 10-Q · filed 2018-08-07 | $34.92M derived: sum of 3 quarters · filed 2018-08-07 | |||
| 2018-03-31 | $34.91M 10-Q · filed 2018-05-09 | $34.92M derived: sum of 2 quarters · filed 2018-05-09 | ||||
| 2017-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | $34.91M 10-K · filed 2018-04-02 | ||||
| 2017-09-30 | $34.90M 10-Q · filed 2017-11-09 | |||||
| 2017-07-04 | $34.91M 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |